Overview

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

This Phase II, randomized, open-label, international, multicenter trial is designed to evaluate the safety and efficacy of rituximab monotherapy when given according to a dose intense regimen and to assess the safety, efficacy, and pharmacokinetics of ABT-263 when combined with dose-intense rituximab in previously untreated patients with B-cell CLL.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

AbbVie (prior sponsor, Abbott)

Treatments:

Navitoclax
Rituximab